255 related articles for article (PubMed ID: 24919109)
1. Use of amyloid PET across the spectrum of Alzheimer's disease: clinical utility and associated ethical issues.
Leuzy A; Zimmer ER; Heurling K; Rosa-Neto P; Gauthier S
Amyloid; 2014 Sep; 21(3):143-8. PubMed ID: 24919109
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of (11)C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment.
Omachi Y; Ito K; Arima K; Matsuda H; Nakata Y; Sakata M; Sato N; Nakagome K; Motohashi N
Psychiatry Clin Neurosci; 2015 Dec; 69(12):741-51. PubMed ID: 26085054
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.
Vallabhajosula S
Semin Nucl Med; 2011 Jul; 41(4):283-99. PubMed ID: 21624562
[TBL] [Abstract][Full Text] [Related]
5. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
6. Flutemetamol (18F): a β-amyloid positron emission tomography tracer for Alzheimer's and dementia diagnosis.
de Lartigue J
Drugs Today (Barc); 2014 Mar; 50(3):219-29. PubMed ID: 24696867
[TBL] [Abstract][Full Text] [Related]
7. Amyloid imaging with PET in early Alzheimer disease diagnosis.
Rowe CC; Villemagne VL
Med Clin North Am; 2013 May; 97(3):377-98. PubMed ID: 23642577
[TBL] [Abstract][Full Text] [Related]
8. Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study.
Fleisher AS; Chen K; Quiroz YT; Jakimovich LJ; Gomez MG; Langois CM; Langbaum JB; Ayutyanont N; Roontiva A; Thiyyagura P; Lee W; Mo H; Lopez L; Moreno S; Acosta-Baena N; Giraldo M; Garcia G; Reiman RA; Huentelman MJ; Kosik KS; Tariot PN; Lopera F; Reiman EM
Lancet Neurol; 2012 Dec; 11(12):1057-65. PubMed ID: 23137949
[TBL] [Abstract][Full Text] [Related]
9. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
[TBL] [Abstract][Full Text] [Related]
10. Molecular neuroimaging in degenerative dementias.
Jiménez Bonilla JF; Carril Carril JM
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):301-9. PubMed ID: 23933381
[TBL] [Abstract][Full Text] [Related]
11. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
12. Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment.
Mattsson N; Tosun D; Insel PS; Simonson A; Jack CR; Beckett LA; Donohue M; Jagust W; Schuff N; Weiner MW;
Brain; 2014 May; 137(Pt 5):1550-61. PubMed ID: 24625697
[TBL] [Abstract][Full Text] [Related]
13. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
Tosun D; Schuff N; Jagust W; Weiner MW;
Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
[TBL] [Abstract][Full Text] [Related]
14. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW;
J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335
[TBL] [Abstract][Full Text] [Related]
15. Molecular imaging of dementia.
Mori T; Maeda J; Shimada H; Higuchi M; Shinotoh H; Ueno S; Suhara T
Psychogeriatrics; 2012 Jun; 12(2):106-14. PubMed ID: 22712644
[TBL] [Abstract][Full Text] [Related]
16. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
[TBL] [Abstract][Full Text] [Related]
17. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
[TBL] [Abstract][Full Text] [Related]
18. Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer's disease - the case of florbetapir.
Hornberger J; Bae J; Watson I; Johnston J; Happich M
Curr Med Res Opin; 2017 Apr; 33(4):675-685. PubMed ID: 28035842
[TBL] [Abstract][Full Text] [Related]
19. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.
Johnson KA; Minoshima S; Bohnen NI; Donohoe KJ; Foster NL; Herscovitch P; Karlawish JH; Rowe CC; Carrillo MC; Hartley DM; Hedrick S; Pappas V; Thies WH
J Nucl Med; 2013 Mar; 54(3):476-90. PubMed ID: 23359661
[TBL] [Abstract][Full Text] [Related]
20. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.
Ikonomovic MD; Buckley CJ; Heurling K; Sherwin P; Jones PA; Zanette M; Mathis CA; Klunk WE; Chakrabarty A; Ironside J; Ismail A; Smith C; Thal DR; Beach TG; Farrar G; Smith AP
Acta Neuropathol Commun; 2016 Dec; 4(1):130. PubMed ID: 27955679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
